NAV

Tofogliflozin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tofogliflozin
DrugBank Accession Number
DB11824
Background

Tofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 386.444
Monoisotopic: 386.172938557
Chemical Formula
C22H26O6
Synonyms
  • Tofogliflozin
  • Tofogliflozin anhydrous
External IDs
  • CSG 452
  • CSG-452
  • R-7201
  • RO-4998452
  • RO4998452
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Tofogliflozin.
AcebutololThe therapeutic efficacy of Tofogliflozin can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Tofogliflozin can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Tofogliflozin.
Acetyl sulfisoxazoleThe therapeutic efficacy of Tofogliflozin can be increased when used in combination with Acetyl sulfisoxazole.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Tofogliflozin hydrateP8DD8KX4O41201913-82-7ZXOCGDDVNPDRIW-NHFZGCSJSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as isocoumarans. These are compounds containing the coumaran skeleton, which consists of a benzene ring fused to a 1,3-dihydrofuran ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isocoumarans
Sub Class
Not Available
Direct Parent
Isocoumarans
Alternative Parents
Isobenzofurans / Ketals / Oxanes / Monosaccharides / Benzene and substituted derivatives / Secondary alcohols / Polyols / Oxacyclic compounds / Primary alcohols / Hydrocarbon derivatives
Substituents
Acetal / Alcohol / Aromatic heteropolycyclic compound / Benzenoid / Hydrocarbon derivative / Isobenzofuran / Isocoumaran / Ketal / Monocyclic benzene moiety / Monosaccharide
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
554245W62T
CAS number
903565-83-3
InChI Key
VWVKUNOPTJGDOB-BDHVOXNPSA-N
InChI
InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1
IUPAC Name
(1S,3'R,4'S,5'S,6'R)-6-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)-3H-spiro[2-benzofuran-1,2'-oxane]-3',4',5'-triol
SMILES
CCC1=CC=C(CC2=CC=C3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=C2)C=C1

References

General References
Not Available
PubChem Compound
46908929
PubChem Substance
347828171
ChemSpider
28530778
BindingDB
50396779
ChEBI
136041
ChEMBL
CHEMBL2110731
ZINC
ZINC000035826342
Wikipedia
Tofogliflozin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD1
4CompletedTreatmentType 2 Diabetes Mellitus2
2CompletedTreatmentType 2 Diabetes Mellitus1
2RecruitingTreatmentMetformin / SGLT 2 Inhibitors / Type 2 Diabetes Mellitus1
2RecruitingTreatmentNash1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.327 mg/mLALOGPS
logP1.5ALOGPS
logP2.47Chemaxon
logS-3.1ALOGPS
pKa (Strongest Acidic)12Chemaxon
pKa (Strongest Basic)-3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area99.38 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity103.33 m3·mol-1Chemaxon
Polarizability41.48 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-dc4bb9e1b0c9e74095a5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-4ed43b219ad984ad9910
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0699-1189000000-c064d7c7dcd4e88ddf64
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kr-0096000000-2ee72b8068fae37fac91
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0670-1093000000-fcfeaf3e44ad8bcacf27
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0191000000-07f8832efd164ab0002e
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-212.1551277
predicted
DarkChem Lite v0.1.0
[M-H]-188.19072
predicted
DeepCCS 1.0 (2019)
[M+H]+215.9478277
predicted
DarkChem Lite v0.1.0
[M+H]+190.58629
predicted
DeepCCS 1.0 (2019)
[M+Na]+211.8831277
predicted
DarkChem Lite v0.1.0
[M+Na]+196.85524
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 20:51 / Updated at February 21, 2021 18:53